Checkpoint Therapeutics Inc’s Post

In case you missed it: Checkpoint Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted approval for UNLOXCYT (cosibelimab-ipdl), a treatment for adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are ineligible for curative surgery or radiation. Read below for insights from James Oliviero, CFA, President and Chief Executive Officer of Checkpoint, on this significant milestone.

  • text
Scott C. Wilcoxen

I help my clients make more money, save more money, and improve user experiences.

3w

Outstanding news, and better yet hope for patients who need differentiated treatment options!

Jan Willem van Dorssen

CMN - HKR - Mailbestand - Sales | Content | BusDev | Leadgen

3w

Congratulations to the team! Looking forward to hear about the commercial planning, but this major one is in the pocket!

Scott Szur

Owner, The Harrison Group, LLC (scott@harrisongroup.com)

3w

James - Congratulations to you and everyone at Checkpoint!! And thanks for providing patients with a much needed treatment option!!

Debora Manning

Biostatistician and Regulatory Consultant

1w

Congratulations to the whole team!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics